Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

PT Kalbe Farma Tbk (LCLA.SG)

Compare
0.0545
+0.0030
+(5.83%)
At close: April 11 at 8:12:54 AM GMT+2
Currency in IDR All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
32,627,776,108.0260
32,627,776,108.0260
30,449,134,077.6180
28,933,502,646.7190
26,261,194,512.3130
Cost of Revenue
19,670,735,916.1280
19,670,735,916.1280
18,625,888,544.2340
17,230,235,543.1710
14,977,410,271.0490
Gross Profit
12,957,040,191.8980
12,957,040,191.8980
11,823,245,533.3840
11,703,267,103.5480
11,283,784,241.2640
Operating Expense
8,889,593,837.1970
8,889,593,837.1970
8,198,108,504.3600
7,478,612,740.8750
7,279,598,645.8370
Operating Income
4,067,446,354.7010
4,067,446,354.7010
3,625,137,029.0240
4,224,654,362.6730
4,004,185,595.4270
Net Non Operating Interest Income Expense
109,866,214.7090
109,866,214.7090
-6,886,246.3790
26,768,042.3240
53,407,759.2960
Pretax Income
4,218,874,269.5230
4,218,874,269.5230
3,606,237,203.8100
4,458,896,905.3500
4,143,264,634.7740
Tax Provision
972,304,515.3260
972,304,515.3260
827,832,384.3090
1,008,813,493.0590
911,256,951.4930
Net Income Common Stockholders
3,240,636,626.3310
3,240,636,626.3310
2,766,748,040.0550
3,382,209,769.0150
3,183,621,310.0430
Diluted NI Available to Com Stockholders
3,240,636,626.3310
3,240,636,626.3310
2,766,748,040.0550
3,382,209,769.0150
3,183,621,310.0430
Basic EPS
66.76
70.16
59.81
72.71
67.92
Diluted EPS
66.76
70.16
59.81
72.71
67.92
Basic Average Shares
46,116,038.0820
46,186,866.6470
46,255,641.4100
46,515,940.5260
46,872,947.1100
Diluted Average Shares
46,149,181.2100
46,186,866.6470
46,255,641.4100
46,515,940.5260
46,872,947.1100
Rent Expense Supplemental
111,284,993.7670
111,284,993.7670
98,288,702.7690
96,661,221.1610
100,799,402.2340
Total Expenses
28,560,329,753.3250
28,560,329,753.3250
26,823,997,048.5940
24,708,848,284.0460
22,257,008,916.8860
Net Income from Continuing & Discontinued Operation
3,240,636,626.3310
3,240,636,626.3310
2,766,748,040.0550
3,382,209,769.0150
3,183,621,310.0430
Normalized Income
3,247,370,621.2687
3,247,370,621.2687
2,753,694,582.7354
3,370,492,781.2103
3,163,633,340.9718
Interest Income
179,100,581.0030
179,100,581.0030
88,217,597.4670
81,827,367.7380
110,792,114.4450
Interest Expense
56,320,229.4930
56,320,229.4930
82,958,206.7530
41,225,899.5960
45,485,899.8930
Net Interest Income
109,866,214.7090
109,866,214.7090
-6,886,246.3790
26,768,042.3240
53,407,759.2960
EBIT
4,275,194,499.0160
4,275,194,499.0160
3,689,195,410.5630
4,500,122,804.9460
4,188,750,534.6670
EBITDA
4,614,036,521.5380
4,614,036,521.5380
4,022,845,625.1170
4,833,897,508.1520
4,536,831,893.6430
Reconciled Cost of Revenue
19,670,735,916.1280
19,670,735,916.1280
18,625,888,544.2340
17,230,235,543.1710
14,977,410,271.0490
Reconciled Depreciation
338,842,022.5220
338,842,022.5220
333,650,214.5540
333,774,703.2060
348,081,358.9760
Net Income from Continuing Operation Net Minority Interest
3,240,636,626.3310
3,240,636,626.3310
2,766,748,040.0550
3,382,209,769.0150
3,183,621,310.0430
Total Unusual Items Excluding Goodwill
-8,750,736.9700
-8,750,736.9700
16,942,766.2570
15,143,065.9550
25,623,529.8580
Total Unusual Items
-8,750,736.9700
-8,750,736.9700
16,942,766.2570
15,143,065.9550
25,623,529.8580
Normalized EBITDA
4,622,787,258.5080
4,622,787,258.5080
4,005,902,858.8600
4,818,754,442.1970
4,511,208,363.7850
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0002
0.0002
Tax Effect of Unusual Items
-2,016,742.0323
-2,016,742.0323
3,889,308.9374
3,426,078.1503
5,635,560.7868
12/31/2021 - 5/13/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade